Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4780-4789

  Nagase, Tsuyoshi ^a   Mizutani, Takashi ^a   Ishikawa, Shiho ^a   Sekino, Etsuko ^a   Sasaki, Takahide ^a   Fujimura, Takashi ^a   Ito, Sayaka ^a   Mitobe, Yuko ^a   Miyamoto, Yasuhisa ^a   Yoshimoto, Ryo ^a   Tanaka, Takeshi ^a   Ishihara, Akane ^a   Takenaga, Norihiro ^a   Tokita, Shigeru ^a   Fukami, Takehiro ^a   Sato, Nagaaki ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 [4 [[3 (1 PIPERIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 5 (TRIFLUOROMETHYL) 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 7 (TRIFLUOROMETHYL) 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 8 (TRIFLUOROMETHYL) 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (2 METHYL 1 PIPERIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (2 METHYL 1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (3 METHYL 1 PIPERIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (3 METHYL 1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (3,5 DIMETHYL 1 PIPERIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2 METHYL 3 [4 [[3 (4 METHYL 1 PIPERIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2,5 DIMETHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2,6 DIMETHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2,7 DIMETHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 2,8 DIMETHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 3 [4 [[3 (1 AZEPANYL)PROPYL]OXY]PHENYL] 2 METHYL 4(3H) QUINAZOLINONE; 3 [4 [[3 (1 AZOCANYL)PROPYL]OXY]PHENYL] 2 METHYL 4(3H) QUINAZOLINONE; 3 [4 [[3 (2,5 DIMETHYL 1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 3 [4 [[3 (DIETHYLAMINO)PROPYL]OXY]PHENYL] 2 METHYL 4(3H) QUINAZOLINONE; 5 FLUORO 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 5 METHOXY 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 6 FLUORO 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 6 METHOXY 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 7 FLUORO 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 7 METHOXY 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 8 FLUORO 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; 8 METHOXY 2 METHYL 3 [4 [[3 (1 PYRROLIDINYL)PROPYL]OXY]PHENYL] 4(3H) QUINAZOLINONE; HISTAMINE H3 RECEPTOR AGONIST; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG SYNTHESIS; HISTAMINE BLOOD LEVEL; HUMAN; HUMAN CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMINES; ANIMALS; CELL LINE; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; LIVER; MOLECULAR STRUCTURE; QUINAZOLINONES; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449107099     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8003834     Document Type: Article

References (49)

1. Brown, R. E.; Stevens, D. R.; Haas, H. L. The physiology of brain histamine. Prog. Neurobiol. 2001, 63, 637-672.
2. (a) Arrang, J. M. Pharmacological properties of histamine receptor subtypes. Cell. Mol. Biol. (Paris) 1994, 40, 275-281.
3. (b) Parsons, M. E.; Ganellin, C. R. Histamine and its receptors. Br. J. Pharmacol. 2006, 147, S127-S135.
4. Lovenberg, T. W.; Roland, B. L.; Wilson, S. J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M. R.; Erlander, M. G. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 1999, 55, 1101-1107.
5. 3 receptor in developing rat tissues. Mech. Dev. 2001, 105, 167-173.
6. Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000, 275, 36781-36786.
7. 3) of histamine receptor. Nature 1983, 302, 832-837.
8. 3 receptor antagonists reach out for the clinic. Drug Discovery Today 2005, 10, 1613-1627.
9. 3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discovery 2005, 4, 107-120.
10. 3 receptors. Eur. J. Pharmacol. 2002, 453, 33-41.
11. 3 heteroreceptors. Fundam. Clin. Pharmacol. 1994, 8, 128-137.
12. 3 receptor subtypes. Br. J. Pharmacol. 1992, 107, 919-923.
13. 3 receptors regulates histamine neurons in brain. Nature 2000, 408, 860-864.
14. 3 receptor. Trends Pharmacol. Sci. 2007, 28, 350-357.
15. 3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol. Ther. 2004, 103, 1-20.
16. 3 Receptor Antagonists: Preclinical Promise for Treating Obesity and Cognitive Disorders. Mol. Interventions 2006, 6, 77-88.
17. 3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J.Pharmacol. Sci. 2006, 101, 12-18.
18. 3-receptor improves wakefulness in narcolepsy: Studies in orexin-/-mice and patients. Neurobiol. Dis. 2008, 30, 74-83.
19. 3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450. Br. J. Pharmacol. 1992, 107, 161-164.
20. 3 receptor in rat cerebral cortex. Br. J. Pharmacol. 1996, 118, 2045-2052.
21. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 2002, 66, 128-135.
22. 3 antagonists. Expert Opin. Ther. Pat. 2007, 17, 675-687.
23. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin. Investig. Drugs 2007, 16, 967-985.
24. 3 receptor. Prog. Med. Chem. 2006, 44, 181-206.
25. 3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 365-375.
26. 3-receptor inverse agonists studied with BF2.649. Biochem. Pharmacol. 2007, 73, 1215-1224.
27. 3 Receptor Antagonists Potently Enhance Cognition and Attention. J. Med. Chem. 2005, 48, 38-55.
28. 3 receptor antagonist with drug-like properties. J. Pharmacol. Exp. Ther. 2005, 313, 165-175.
29. 3 receptor antagonist. J. Pharmacol. Exp. Ther. 2005, 313, 176-190.
30. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 2007, 321, 1032-1045.
31. Errede, L. A. Acylanthranils. The pathway of quinazolone formation in the reaction of acylanthranils with anilines. J. Org. Chem. 1976, 41, 1763-1765.
32. Botros, S.; Saad, S. F. Synthesis, antihypertensive and β-adrenoreceptor antagonist activities of 3-[4-[3-(4-aryl-1-piperazinyl)- isopropanoloxy]phenyl]-4(3H)-quinazolones. Eur. J. Med. Chem. 1989, 24, 585-590.
33. See Supporting Information for the preparation of compounds and references cited therein.
34. Kumari, T. A.; Reddy, M. S.; Rao, P. J. P. A facile synthesis of 2,3-disubstituted pyrido[2,3-h]quinazolin-4(3H)-ones. Synth. Commun. 2002, 32, 235-240.
35. 3- catalyzed one-pot synthesis of quinazolin-4(3H)-ones from anthranilic acid, amines and ortho esters (or formic acid) in solvent-free conditions. Synthesis 2003, 1241-1247.
36. For hERG binding assay protocol, see the following: Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.; Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo, D. G. Radioligand and binding assay. PCT Int. Appl. WO2002005860, 2002.
37. Shibata, Y.; Takahashi, H.; Ishii, Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos. 2000, 28, 1518-1523.
38. (a) Yamazaki, M.; Neway, W. E.; Ohe, T.; Chen, I-Wu.; Rowe, J. F.; Hochman, J. H.; Chiba, M.; Lin, J. H. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J.Pharmacol. Exp. Ther. 2001, 296, 723-735.
39. (b) Ohe, T.; Sato, M.; Tanaka, S.; Fujino, N.; Hata, M.; Shibata, Y.; Kanatani, A.; Fukami, T.; Yamazaki, M.; Chiba, M.; Ishii, Y. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab. Dispos. 2003, 31, 1251-1254.
40. Miyamoto, Y.; Yoshimoto, R.; Yumoto, M.; Ishihara, A.; Takahashi, K.; Kotani, H.; Kanatani, A.; Tokita, S. Simultaneous fluorometric measurement of histamine and tele-methylhistamine levels in rodent brain by high-performance liquid chromatography. Anal. Biochem. 2004, 334, 89-96.
41. See Supporting Information for experimental details.
42. (a) Lankas, G. R.; Cartwright, M. E.; Umbenhauer, D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 1997, 143, 357-365.
43. (b) Umbenhauer, D. R.; Lankas, G. R.; Pippert, T. R.; Wise, L. D.; Cartwright, M. E.; Hall, S. J.; Beare, C. M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 1991, 146, 88-94.
44. Nijhuis, W. H. N.; Verboom, W.; Abu El-Fadl, A.; Van Hummel, G. J.; Reinhoudt, D. N. Stereochemical aspects of the "tert-amino effect". 2. Enantio- and diastereoselectivity in the synthesis of quinolines, pyrrolo[1,2-a]quinolines, and [1,4]oxazino[4,3-a] quinolines. J. Org. Chem. 1989, 54, 209-216.
45. Zhao, D.; Kuethe, J. T.; Journet, M.; Peng, Z.; Humphrey, G. R. Efficient and Practical Synthesis of (R)-2-Methylpyrrolidine. J. Org. Chem. 2006, 71, 4336-4338.
46. (a) Budhram, R. S.; Pourahmady, N.; Syed, A. S.; Eisenbraun, E. J. 3-Methylsuccinimide and 3-methylpyrrolidine. Org. Prep. Proced. Int. 1986, 18, 295-297.
47. (b) Kondo, K.; Ogawa, H.; Shinohara, T.; Kurimura, M.; Tanada, Y.; Kan, K.; Yamashita, H.; Nakamura, S.; Hirano, T.; Yamamura, Y.; Mori, T.; Tominaga, M.; Itai, A. Novel Design of Nonpeptide AVP V2 Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H- 1-benzazepine as a Template. J. Med. Chem. 2000, 43, 4388-4397.
48. (a) Marwaha, J.; Palmer, M.; Hoffer, B.; Freedman, R.; Rice, K. C.; Paul, S.; Skolnick, P. Differential electrophysiological and behavioral responses to optically active derivatives of phencyclidine. Naunyn-Schmiedeberg's Arch. Pharmacol. 1981, 315, 203-209.
49. (b) Thurkauf, A.; Hillery, P.; Jacobson, A. E.; Rice, K. C. An Efficient Synthesis of Optically Pure (S)-(-)-3-Methylcyclohexanone. J. Org. Chem. 1987, 52, 5466-5467.